Gonadal hormones (estrogens, progestins) US Medical PG Practice Questions and MCQs
Practice US Medical PG questions for Gonadal hormones (estrogens, progestins). These multiple choice questions (MCQs) cover important concepts and help you prepare for your exams.
Gonadal hormones (estrogens, progestins) US Medical PG Question 1: A 58-year-old obese woman presents with painless postmenopausal bleeding for the past 5 days. A recent endometrial biopsy confirmed endometrial cancer, and the patient is scheduled for total abdominal hysterectomy and bilateral salpingo-oophorectomy. Past medical history is significant for stress incontinence and diabetes mellitus type 2. Menarche was at age 11 and menopause was at age 55. The patient has 4 healthy children from uncomplicated pregnancies, who were all formula fed. Current medications are topical estrogen and metformin. Family history is significant for breast cancer in her grandmother at age 80. Which of the following aspects of this patient’s history is associated with a decreased risk of breast cancer?
- A. Early menarche
- B. Formula feeding
- C. Obesity
- D. Endometrial cancer
- E. Multiple pregnancies (Correct Answer)
Gonadal hormones (estrogens, progestins) Explanation: ***Multiple pregnancies***
- Having **multiple full-term pregnancies** is associated with a **decreased lifetime risk of breast cancer**
- This protective effect is related to hormonal changes during pregnancy that lead to **terminal differentiation of mammary epithelial cells**
- The protective effect **increases with the number of completed pregnancies** and is greater with younger age at first full-term pregnancy
- This patient had **4 healthy children**, providing significant protective benefit
*Early menarche*
- **Early menarche** (before age 12) is a **risk factor** for breast cancer because it increases lifetime exposure of breast tissue to estrogens
- This patient's menarche at **age 11** falls into the category of early menarche, thus **increasing** her breast cancer risk
*Formula feeding*
- **Breastfeeding** is protective against breast cancer, reducing risk through hormonal changes and breast tissue differentiation
- **Formula feeding** (lack of breastfeeding) does **not confer this protective benefit** and is associated with relatively higher risk compared to breastfeeding
- This patient formula-fed all 4 children, missing the protective effect of breastfeeding
*Obesity*
- **Obesity**, especially in postmenopausal women, is a **known risk factor** for breast cancer
- Adipose tissue converts androgens into estrogens via aromatase, leading to **higher circulating estrogen levels**
- This increased estrogen exposure stimulates growth of hormone-sensitive breast cancer cells
*Endometrial cancer*
- Both **endometrial cancer** and breast cancer are influenced by **prolonged estrogen exposure**
- They share common risk factors including obesity, nulliparity, late menopause, and unopposed estrogen
- Having endometrial cancer indicates high estrogen exposure, which is a **shared risk factor** rather than a protective factor for breast cancer
Gonadal hormones (estrogens, progestins) US Medical PG Question 2: A 19-year-old woman comes to the physician because of a delayed menstrual period. She has had regular menses since menarche at age 11. Her last menstrual period was 7 weeks ago. She is sexually active with two male partners. A urine pregnancy test is positive. An ultrasound of the pelvis shows a viable intrauterine pregnancy with an estimated gestational age of 6 weeks and 5 days. She does not wish to continue with the pregnancy. After carefully weighing the options with her physician, she is prescribed two medications, one of which is mifepristone. Which of the following is this drug's primary mechanism of action?
- A. Activation of prostaglandin E1 receptors
- B. Inhibition of dihydrofolate reductase
- C. Blockage of progesterone receptor (Correct Answer)
- D. Agonist at oxytocin receptors
- E. Antagonist at gonadotropin-releasing hormone receptors
Gonadal hormones (estrogens, progestins) Explanation: ***Blockage of progesterone receptor***
- **Mifepristone** is a **progesterone receptor antagonist**, meaning it blocks the action of progesterone.
- Progesterone is essential for maintaining early pregnancy by supporting the **endometrium** and preventing uterine contractions.
*Activation of prostaglandin E1 receptors*
- This is the primary mechanism of action for **misoprostol**, the second medication often used in medical abortion protocols.
- **Misoprostol** causes **uterine contractions** and cervical ripening, which expels the uterine contents after mifepristone has prepared the uterus.
*Inhibition of dihydrofolate reductase*
- This is the mechanism of action for **methotrexate**, an antifolate drug that can also be used for medical abortion.
- **Methotrexate** inhibits DNA synthesis in rapidly dividing cells, leading to the termination of the pregnancy.
*Agonist at oxytocin receptors*
- **Oxytocin agonists** (like oxytocin itself) are typically used for labor induction or to control postpartum hemorrhage, not for early medical abortion.
- They cause strong uterine contractions but are usually administered later in pregnancy or postpartum.
*Antagonist at gonadotropin-releasing hormone receptors*
- **GnRH antagonists** (e.g., cetrorelix, ganirelix) are used in assisted reproductive technologies to prevent premature ovulation.
- They do not directly cause medical abortion by blocking progesterone's action or directly inducing uterine contractions.
Gonadal hormones (estrogens, progestins) US Medical PG Question 3: A 30-year-old woman presents to a medical clinic for a routine check-up. She gained about 5 kg (11 lb) since the last time she weighed herself 3 months ago. She also complains of constipation and sensitivity to cold. She also noticed her hair appears to be thinning. The patient started to use combined oral contraceptives a few months ago and she is compliant. On physical examination, the temperature is 37.0°C (98.6°F), the blood pressure is 110/70 mm Hg, the pulse is 65/min, and the respiratory rate is 14/min. The laboratory results are as follows:
Thyroxine (T4), total 25 ug/dL
Thyroxine (T4), free 0.8 ng/dL
TSH 0.2 mU/L
Which of the following is the main mechanism of action of the drug that caused her signs and symptoms?
- A. Inhibition of an enzyme in the thyroid gland
- B. Inducing endometrial atrophy
- C. Increase the thickness of cervical mucus secretions
- D. Inhibition of hormones in the pituitary gland (Correct Answer)
- E. Inhibition of hormones in hypothalamus
Gonadal hormones (estrogens, progestins) Explanation: ***Inhibition of hormones in the pituitary gland***
- The patient's symptoms (weight gain, constipation, cold sensitivity, hair thinning) combined with laboratory results showing **low TSH** and **low free T4** are indicative of **central hypothyroidism**.
- **Combined oral contraceptives** contain estrogen, which increases **thyroxine-binding globulin (TBG)** levels. This leads to increased total T4 but a decrease in free T4. The body compensates by increasing TSH to maintain euthyroidism. However, if the patient has central hypothyroidism (pituitary suppression), the TSH will not increase appropriately. Thus, the main mechanism of oral contraceptives relates to its interaction with the **hypothalamic-pituitary-thyroid (HPT) axis**, where the estrogen component of COCs can suppress pituitary TSH secretion over time, leading to central hypothyroidism in susceptible individuals. The primary action of combined oral contraceptives (COCs) in preventing pregnancy is the **inhibition of gonadotropins (FSH and LH) from the pituitary gland**, thereby preventing ovulation. While this is the main contraceptive mechanism, the estrogen component of COCs is known to affect thyroid hormone binding and metabolism, which can unmask or exacerbate underlying thyroid dysregulation, leading to the observed picture of central hypothyroidism with suppressed TSH and low free T4.
*Inhibition of an enzyme in the thyroid gland*
- This mechanism of action is associated with **antithyroid drugs** like methimazole or propylthiouracil, used to treat **hyperthyroidism**, not hypothyroidism.
- These drugs block thyroid hormone synthesis, leading to high TSH and low thyroid hormones, a picture of primary hypothyroidism, which is not what's observed here (TSH is low).
*Inducing endometrial atrophy*
- While combined oral contraceptives can cause **endometrial thinning**, this is a direct effect on the uterus and not the primary mechanism responsible for the systemic symptoms or the thyroid abnormalities described.
- Endometrial atrophy is also seen in conditions like menopause or progestin-only contraception, but it does not explain the thyroid dysfunction.
*Increase the thickness of cervical mucus secretions*
- This is a primary contraceptive mechanism of **progestin-only contraceptives**, designed to impede sperm passage, but it is not the main mechanism of combined oral contraceptives leading to the observed systemic symptoms.
- While combined oral contraceptives also affect cervical mucus, it's not the critical factor explaining the thyroid profile and symptoms in this case.
*Inhibition of hormones in hypothalamus*
- While oral contraceptives do influence the **hypothalamus-pituitary-ovarian axis**, the direct cause of the thyroid dysfunction in this scenario is due to direct effects on the liver (TBG) and the pituitary (TSH suppression), rather than primarily inhibiting hypothalamic hormones.
- The direct and primary site of action for inducing the thyroid hormone changes due to COCs is more downstream at the pituitary and liver levels not the hypothalamus.
Gonadal hormones (estrogens, progestins) US Medical PG Question 4: A researcher is studying physiologic and hormonal changes that occur during pregnancy. Specifically, they examine the behavior of progesterone over the course of the menstrual cycle and find that it normally decreases over time; however, during pregnancy this decrease does not occur in the usual time frame. The researcher identifies a circulating factor that appears to be responsible for this difference in progesterone behavior. In order to further examine this factor, the researcher denatures the circulating factor and examines the sizes of its components on a western blot as compared to several other hormones. One of the bands the researcher identifies in this circulating factor is identical to that of another known hormone with which of the following sites of action?
- A. Thyroid gland (Correct Answer)
- B. Adrenal gland
- C. Adipocytes
- D. Bones
- E. Kidney tubules
Gonadal hormones (estrogens, progestins) Explanation: ***Correct: Thyroid gland***
- The circulating factor described is **human chorionic gonadotropin (hCG)**, which maintains the corpus luteum and progesterone production during early pregnancy
- hCG is a **glycoprotein hormone** composed of an **α subunit** and a **β subunit**
- The **α subunit of hCG is identical** to the α subunits of **TSH (thyroid-stimulating hormone)**, **LH (luteinizing hormone)**, and **FSH (follicle-stimulating hormone)**
- When denatured and examined on Western blot, one of the bands (the α subunit) would be identical to that of **TSH**
- **TSH acts on the thyroid gland** to stimulate thyroid hormone synthesis and release
- This structural similarity explains why very high levels of hCG (as in molar pregnancy or hyperemesis gravidarum) can sometimes cause **thyrotoxicosis** due to cross-reactivity with TSH receptors
*Incorrect: Adrenal gland*
- **ACTH (adrenocorticotropic hormone)** acts on the adrenal cortex to stimulate cortisol production
- ACTH is a **peptide hormone** derived from POMC (pro-opiomelanocortin) and does **NOT share any structural components** with hCG
- There is no identical band between hCG and ACTH on Western blot
*Incorrect: Adipocytes*
- Adipocytes are regulated by hormones like **insulin** and **leptin**
- Neither of these hormones share structural components with hCG
*Incorrect: Bones*
- Bones are primarily regulated by **PTH (parathyroid hormone)**, **calcitonin**, and **vitamin D**
- None of these hormones share structural components with hCG
*Incorrect: Kidney tubules*
- Kidney tubules are regulated by **ADH (antidiuretic hormone/vasopressin)** and **aldosterone**
- Neither shares structural components with hCG
Gonadal hormones (estrogens, progestins) US Medical PG Question 5: A 51-year-old woman presents to the primary care clinic complaining of trouble sleeping. She reports that she has episodes of "overheating" and "sweating" during the day and at night. The nightly episodes keep her from staying asleep. She also explains how embarrassing it is when she suddenly becomes hot and flushed during work meetings. The patient becomes visibly upset and states that she is worried about her marriage as well. She says she has been fighting with her husband about not going out because she is "too tired." They have not been able to have sex the past several months because "it hurts." Labs are drawn, as shown below:
Follicle stimulating hormone (FSH): 62 mIU/mL
Estradiol: 34 pg/mL
Progesterone: 0.1 ng/mL
Luteinizing hormone (LH): 46 mIU/mL
Free testosterone: 2.1 ng/dL
Which of the following contributes most to the production of estrogen in this patient?
- A. Adrenal glands
- B. Adipose tissue (Correct Answer)
- C. Bartholin glands
- D. Mammary glands
- E. Ovaries
Gonadal hormones (estrogens, progestins) Explanation: **Adipose tissue**
- In **postmenopausal women**, the ovaries no longer produce significant amounts of estrogen; instead, **adipose tissue** becomes the primary site for estrogen synthesis through the conversion of **androgens** (like androstenedione from the adrenal glands) into **estrone** via **aromatase**.
- The patient's presentation with **hot flashes**, **night sweats**, **sleep disturbance**, **vaginal dryness** (painful intercourse), and **elevated FSH/LH** with **low estradiol** is classic for **menopause**, highlighting the shift in estrogen production.
*Adrenal glands*
- The **adrenal glands** primarily produce **androgens** (e.g., androstenedione, DHEA) and a small amount of estrogens, but their main contribution to estrogen in menopause is indirect, by providing substrates for conversion in peripheral tissues.
- While they are a source of **androgens**, they do not directly contribute most significantly to **estrogen production** in a menopausal woman compared to the peripheral conversion in adipose tissue.
*Bartholin glands*
- **Bartholin glands** are located at the vaginal opening and produce **lubricating fluid**, but they play no role in **hormone production**, including estrogen.
- They are exocrine glands involved in lubrication during sexual arousal.
*Mammary glands*
- **Mammary glands** are primarily involved in **milk production** (lactation) and are target organs for sex hormones, but they do not produce significant amounts of **estrogen**.
- They respond to estrogen but do not synthesize it in substantial quantities.
*Ovaries*
- In premenopausal women, the **ovaries** are the primary source of **estrogen** (mainly estradiol), but in this 51-year-old woman with menopausal symptoms and high FSH/LH, ovarian function has significantly declined.
- The **elevated FSH and LH** levels, coupled with **low estradiol**, indicate **ovarian failure**, meaning the ovaries are no longer actively producing estrogen.
Gonadal hormones (estrogens, progestins) US Medical PG Question 6: A 31-year-old woman makes an appointment with a fertility specialist because she has not been able to conceive despite trying for over a year with her husband. She is concerned because her husband has 2 children from a previous marriage whereas she has no children. After obtaining a detailed history as well as lab tests, the specialist prescribes a certain drug. Interestingly, this drug is able to stimulate receptors in the presence of low hormone levels and inhibit the same receptors in the presence of high hormone levels. The drug that is most likely being prescribed in this case is associated with which of the following adverse events?
- A. Hirsutism
- B. Deep venous thrombosis
- C. Thrombophilia
- D. Osteoporosis
- E. Visual disturbances (Correct Answer)
Gonadal hormones (estrogens, progestins) Explanation: ***Visual disturbances***
- The description of the drug activating receptors in low hormone states and inhibiting them in high hormone states, coupled with its use for infertility, strongly suggests **clomiphene citrate**, a selective estrogen receptor modulator (SERM).
- **Visual disturbances** such as blurred vision, scotomas, or photopsia are a relatively common adverse effect of clomiphene due to its effect on estrogen receptors in the retina.
*Hirsutism*
- **Hirsutism** (excessive hair growth) is typically associated with conditions causing androgen excess, like **polycystic ovary syndrome (PCOS)**, and is not a direct common adverse effect of clomiphene.
- While clomiphene aims to induce ovulation, it does not directly cause an increase in androgens leading to hirsutism.
*Deep venous thrombosis*
- Although some hormonal treatments can increase the risk of **DVT**, clomiphene's association with DVT is **not as primary or common** as other adverse effects, and it's less direct compared to estrogen-containing medications.
- The mechanism of action of clomiphene as a SERM modulating estrogen receptors does not typically lead to a significant procoagulant state comparable to exogenous estrogen.
*Thrombophilia*
- **Thrombophilia** refers to an increased tendency to form blood clots; while some hormonal medications can exacerbate thrombophilia, clomiphene is **not generally recognized** for causing thrombophilia or significantly increasing its risk.
- Its mechanism of action primarily involves stimulating gonadotropin release rather than directly altering coagulation factors to induce thrombophilia.
*Osteoporosis*
- While **estrogen deficiency** can lead to osteoporosis, clomiphene's role is to modulate estrogen receptors; it can cause some anti-estrogenic effects, but **osteoporosis is not a common acute or direct adverse event** of its short-term use for fertility.
- Long-term use of anti-estrogenic drugs like tamoxifen can increase osteoporosis risk, but clomiphene is typically used for a limited duration, making osteoporosis less relevant as an immediate adverse event.
Gonadal hormones (estrogens, progestins) US Medical PG Question 7: A 69-year-old woman comes to the clinic for an annual well exam. She reports no significant changes to her health except for an arm fracture 3 weeks ago while she was lifting some heavy bags. Her diabetes is well controlled with metformin. She reports some vaginal dryness that she manages with adequate lubrication. She denies any weight changes, fevers, chills, palpitations, nausea/vomiting, incontinence, or bowel changes. A dual-energy X-ray absorptiometry (DEXA) scan was done and demonstrated a T-score of -2.7. She was subsequently prescribed a selective estrogen receptor modulator, in addition to vitamin and weight-bearing exercises, for the management of her symptoms. What is the mechanism of action of the prescribed medication?
- A. Estrogen antagonist in cervix and agonist in bone
- B. Estrogen agonist in bone and breast
- C. Estrogen antagonist in breast and agonist in bone (Correct Answer)
- D. Partial estrogen agonist in endometrium and bone
- E. Partial estrogen agonist in bone and antagonist in cervix
Gonadal hormones (estrogens, progestins) Explanation: ***Estrogen antagonist in breast and agonist in bone***
- Selective estrogen receptor modulators (SERMs) like **raloxifene** act as **estrogen agonists in bone**, helping to prevent osteoporosis by increasing bone mineral density.
- They also act as **estrogen antagonists in breast tissue**, which can reduce the risk of breast cancer in high-risk postmenopausal women.
- This is the mechanism of the medication prescribed for this patient's osteoporosis (T-score -2.7).
*Estrogen antagonist in cervix and agonist in bone*
- While SERMs are **agonists in bone**, they do not typically have significant antagonistic effects on the cervix, which is not a primary target for their therapeutic action or side effect profile.
- The primary antagonism is observed in breast tissue, not the cervix.
*Estrogen agonist in bone and breast*
- This describes the action of **estrogen replacement therapy (ERT)**, which increases breast cancer risk, whereas SERMs are designed to avoid this by being antagonists in breast tissue.
- The goal of SERMs is to achieve the beneficial bone effects of estrogen without the undesirable estrogenic effects on breast tissue.
*Partial estrogen agonist in endometrium and bone*
- Some SERMs, particularly **tamoxifen**, can act as a **partial estrogen agonist in the endometrium**, which can increase the risk of endometrial hyperplasia or cancer.
- However, raloxifene (a common SERM for osteoporosis) is typically **neutral or minimally agonistic** on the endometrium, and the primary description here is for its breast and bone effects.
*Partial estrogen agonist in bone and antagonist in cervix*
- SERMs are indeed **agonists in bone**, but their antagonistic action is primarily in the breast, not the cervix.
- The cervix is not a key target for either agonist or antagonist effects in the context of SERM therapeutic use for osteoporosis and breast cancer risk reduction.
Gonadal hormones (estrogens, progestins) US Medical PG Question 8: A 40-year-old man presents with a painless firm mass in the right breast. Examination shows retraction of the nipple and the skin is fixed to the underlying mass. The axillary nodes are palpable. Which of the following statements is FALSE regarding the above condition?
- A. Lobular cancer is the most common breast cancer in males (Correct Answer)
- B. BRCA2 mutations are associated with increased risk
- C. These are positive for estrogen receptor
- D. Endocrine therapy plays an important role in treatment
- E. Gynecomastia may be caused by certain medications
Gonadal hormones (estrogens, progestins) Explanation: ***Lobular cancer is the most common breast cancer in males***
- This statement is **FALSE** and is the correct answer. The most common type of breast cancer in males is **invasive ductal carcinoma (IDC)**, accounting for about 80-90% of cases.
- **Invasive lobular carcinoma** is rare in men because men have very few lobules in their breast tissue.
*Gynecomastia may be caused by certain medications*
- This statement is **TRUE**. Medications such as spironolactone, cimetidine, finasteride, antipsychotics, and anabolic steroids can cause gynecomastia.
- However, the clinical presentation described (firm mass, nipple retraction, skin fixation, axillary nodes) is consistent with **malignancy**, not gynecomastia.
*BRCA2 mutations are associated with increased risk*
- This statement is **TRUE**. Male breast cancer is strongly associated with **BRCA2 mutations** (and less commonly BRCA1), which are hereditary.
- Men with BRCA2 mutations have a 5-10% lifetime risk of developing breast cancer, compared to less than 0.1% in the general male population.
*These are positive for estrogen receptor*
- This statement is **TRUE**. A vast majority (over 90%) of male breast cancers are **estrogen receptor (ER) positive**, which makes them responsive to endocrine therapy.
- This high rate of ER positivity is even greater than in female breast cancers.
*Endocrine therapy plays an important role in treatment*
- This statement is **TRUE**. Given the high prevalence of ER positivity (over 90%), endocrine therapy such as **tamoxifen** or aromatase inhibitors is a cornerstone of treatment for male breast cancer.
- Endocrine therapy is used in both adjuvant and metastatic settings for hormone receptor-positive disease.
Gonadal hormones (estrogens, progestins) US Medical PG Question 9: A 21-year-old G2P1 woman presents to the clinic and is curious about contraception immediately after her baby is born. She is anxious about taking care of one child and does not believe that she can handle the responsibility of caring for another. She has no other questions or complaints today. Her past medical history consists of generalized anxiety disorder, antithrombin deficiency, and chronic deep vein thrombosis. She has been hospitalized for acute on chronic deep vein thrombosis. Her only medication is buspirone. Her blood pressure is 119/78 mm Hg and the heart rate is 78/min. BMI of the patient is 32 kg/m2. On physical examination, her fundal height is 21 cm from pubic symphysis. No ovarian masses are palpated during the bimanual examination. Ultrasound exhibits a monoamniotic, monochorionic fetus. Which of the following forms of contraception would be the most detrimental given her risk factors?
- A. Copper IUD
- B. Transdermal contraceptive patch (Correct Answer)
- C. Norethindrone
- D. Depot medroxyprogesterone acetate
- E. Levonorgestrel IUD
Gonadal hormones (estrogens, progestins) Explanation: ***Transdermal contraceptive patch***
- The transdermal contraceptive patch contains **estrogen**, which significantly increases the risk of **thromboembolism**. With a history of **antithrombin deficiency** and **recurrent deep vein thrombosis (DVT)**, estrogen-containing contraception is absolutely contraindicated due to the high risk of fatal clotting events.
- The patient's underlying **antithrombin deficiency** makes her particularly susceptible to prothrombotic effects, and combined hormonal contraceptives like the patch further exacerbate this risk.
*Copper IUD*
- The **copper IUD** is a **non-hormonal** contraceptive option, making it safe for individuals with a history of thromboembolism.
- Its mechanism of action involves creating a local inflammatory reaction in the uterus to prevent fertilization and implantation, thus posing no systemic clotting risk.
*Norethindrone*
- **Norethindrone** is a **progestin-only pill**, which does not contain estrogen and is generally considered safe for individuals with a history of thromboembolism.
- Progestin-only contraceptives avoid the estrogen-induced increase in clotting factors, making them a suitable option in this high-risk patient.
*Depot medroxyprogesterone acetate*
- **Depot medroxyprogesterone acetate (DMPA)** is an injectable **progestin-only contraceptive** that is safe for patients with a history of **thromboembolism**.
- It works by suppressing ovulation and thickening cervical mucus and does not carry the same clotting risks as estrogen-containing methods.
*Levonorgestrel IUD*
- The **levonorgestrel IUD** is a **progestin-only** contraceptive that releases hormones locally within the uterus, with minimal systemic absorption.
- It is a safe and highly effective option for patients with a history of thromboembolism due to the absence of estrogen and limited systemic hormonal effects.
Gonadal hormones (estrogens, progestins) US Medical PG Question 10: A 57-year-old woman comes to the physician for evaluation of a lump in the right breast that she first noticed a week ago. Biopsy of the mass confirms a diagnosis of a pleomorphic lobular carcinoma-in-situ that is estrogen receptor-positive. The patient undergoes lumpectomy, and treatment with tamoxifen is initiated. Which of the following conditions is most likely to occur as a result of tamoxifen therapy?
- A. Ovarian cancer
- B. Endometrial cancer (Correct Answer)
- C. Osteoporosis
- D. Myelosuppression
- E. Cardiotoxicity
Gonadal hormones (estrogens, progestins) Explanation: ***Endometrial cancer***
- Tamoxifen acts as an **estrogen receptor agonist** in the **endometrium**, stimulating endometrial proliferation.
- This proliferative effect significantly **increases the risk of endometrial hyperplasia** and **endometrial cancer** in postmenopausal women.
*Ovarian cancer*
- Tamoxifen is not directly linked to an increased risk of ovarian cancer.
- While it affects estrogen receptors, its primary oncogenic risk is specific to the endometrium due to its agonist activity there.
*Osteoporosis*
- Tamoxifen acts as an **estrogen receptor agonist in bone**, which has a protective effect against bone loss.
- Therefore, it typically **reduces the risk of osteoporosis**, especially in postmenopausal women, rather than causing it.
*Myelosuppression*
- Myelosuppression (bone marrow suppression) is a common side effect of many **chemotherapeutic agents**, but it is **not a typical side effect of tamoxifen**.
- Tamoxifen's mechanism of action as a selective estrogen receptor modulator (SERM) does not primarily target rapidly dividing hematopoietic cells.
*Cardiotoxicity*
- **Cardiotoxicity**, such as **cardiomyopathy** or **heart failure**, is a known side effect of certain oncology drugs like **anthracyclines** (e.g., doxorubicin) and some **HER2-targeted therapies** (e.g., trastuzumab).
- Tamoxifen is **not associated with significant cardiotoxicity**.
More Gonadal hormones (estrogens, progestins) US Medical PG questions available in the OnCourse app. Practice MCQs, flashcards, and get detailed explanations.
